The effect of spinally administered WIN 55,212-2, a cannabinoid agonist, on thermal pain sensitivity in diabetic rats

Document Type : Original Article

Authors

1 Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

3 Department of Physical Therapy, Faculty of Rehabilitation Sciences, Tehran University of Medical Sciences, Tehran, Iran

4 Department of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

5 Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Objective(s):Diabetic neuropathy (DN) is a common complication of diabetes that leads to allodynia, impaired nerve conduction, and progressive sensory loss. The aim of this study was to observe the effect of a high-affinity cannabinoid receptors agonist, WIN 55,212-2, on thermal hyperalgesia, nerve conduction velocity and sciatic nerve histopathology in diabetic rats.
Materials and Methods: Diabetes was induced in rats using a single dose of streptozotocin (45 mg/kg IP).
Results: Intrathecal (IT) administration of WIN55, 212-2 (1, 10, 100 µg/10 µl, IT), produced antinociceptive effects in the hot plate test and also improved nerve conduction velocity (100 µg/10 µl, IT) and sciatic nerve histology.
Conclusion: These data show that cannabinoids have potent antinociceptive effects through direct actions in the spinal dorsal horn of nociceptive pathway. This suggests that intrathecally administered cannabinoids may offer hopeful strategies for the treatment of diabetic neuropathic pain.

Keywords

References

1. Hohmann AG,Tsou K, Walker JM. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. Neurosci Lett 1998; 257:119-122.
2. Fox A, Kesingland A, Gentry C, McNair K, Patel S, UrbanL, et al. The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001; 92:91-100.
3. Tsou K, Brown S, Sanudo-Pena M, Mackie K, Walker J. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83:393-411.
4. Hohmann A, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 1999; 90:923-931.
5. Hohmann A, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 1999; 92:1171-1175.
6. Martin WJ, Loo CM, Basbaum AI. Basbaum, Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 1999; 82:199-205.
7.   Li J, Daughters RS, Bullis C, Bengiamin R, Stucky MW, Brennan J, et al. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain 1999; 81:25-33.
8.   Costa B, Siniscalco D, Trovato AE, Comelli F, Sotgiu ML, Colleoni M, et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol 2006; 148:1022-1032.
9. Liang YC, Huang CC, Hsu KS. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacology 2007; 53:169-177.
10. Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J. Cannabinoid CB 1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 2001; 415:R5-R7.
11. Bridges D, Thompson S, Rice A. Mechanisms of neuropathic pain. Br J Anaesth 2001; 87:12-26.
12. Pertwee RG. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch Komplementarmed 1999; 6:12-15.
13. Rice A, Farquhar-Smith W, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 2002; 66:243-256.
14. Vaughan CW, Christie MJ. An analgesic role for cannabinoids. Med J Australia 2000; 173:270-272.
15. Scott DA, Wright CE, Angus JA. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 2004; 109:124-131.
16. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394:277-281.
17. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci 2003; 100:10529-10533.
18. Malan Jr TP, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, et al. CB 2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001; 93:239-245.
19. Malan TP, Ibrahim MM, Vanderah TW, Makriyannis A, Porreca F. Inhibition of pain responses by activation of CB 2 cannabinoid receptors. Chem Phys Lipids 2002; 121:191-200.
20. Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55, 212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 2001; 133:586-594.
21. Hanuš L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D,  HorowitzM, et al. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci 1999; 96:14228-14233.
22. Ulugol A, Karadag HC, Ipci Y, Tamer M, Dokmeci I. The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett 2004; 371:167-170.
23. Mohammadi-Farani A, Sahebgharani M, Sepehrizadeh Z, Jaberi E, Ghazi-Khansari M. Diabetic thermal hyperalgesia: role of TRPV1 and CB1 receptors of periaqueductal gray. Brain Res 2010; 1328:49-56.
24. Becker M, Benromano T, Shahar A, Nevo Z, Pick CG. Changes in the basal membrane of dorsal root ganglia schwann cells explain the biphasic pattern of the peripheral neuropathy in streptozotocin-induced diabetic rats. J Mol Neurosci 2014; 54:704-713.
25. Kafri M, Drory VE, Wang N, Rabinowitz R, Korczyn AD, Chapman J. Assessment of experimental autoimmune neuritis in the rat by electrophysiology of the tail nerve. Muscle Nerve 2002; 25:51-57.
26. Skundric DS, Lisak RP. Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration. J Diabetes Res 2003; 4:303-312.
27. Gerbi A, Maixent JM, Ansaldi JL, Pierlovisi M, Coste T, Pelissier JF, et al. Fish oil supplementation prevents diabetes-induced nerve conduction velocity and neuroanatomical changes in rats. J Nutr 1999; 129:207-213.
28. Sima A, Prashar A, Nathaniel V, Bril V, Werb M, Greene D. Overt diabetic neuropathy: repair of axo‐glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity. Diabet Med 1993; 10:115-121.
29. Siemionow M, Demir Y. Diabetic neuropathy: pathogenesis and treatment. J  Reconstr Microsurg 2004; 20:241-252.
30. Peeraer E, Van Lutsenborg A, Verheyen A, de Jongh R, Nuydens R, Meert TF. Pharmacological evaluation of rat dorsal root ganglion neurons as an in vitro model for diabetic neuropathy. J Pain Res 2011; 4: 55.
31. Hohmann AG, Tsou K, Walker JM. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55, 212-2. Neurosci Lett 1998; 257:119-122.
32. Yang P, Wen H, Ou S, Cui J, Fan D. IL-6 promotes regeneration and functional recovery after cortical spinal tract injury by reactivating intrinsic growth program of neurons and enhancing synapse formation. Exp Neurol 2012;  236:19-27.
33. Kang S, Kim CH, Lee H, Kim DY, Han JI, Chung RK, et al. Antinociceptive synergy between the cannabinoid receptor agonist WIN 55,212-2 and bupivacaine in the rat formalin test. Anesth Analg 2007; 104:719-725.
34. Cui J, He W, Yi B, Zhao H, Lu K, Ruan H, et al.  mTOR pathway is involved in ADP-evoked astrocyte activation and ATP release in the spinal dorsal horn in a rat neuropathic pain model. Neuroscience 2014; 275:395-403.
35. Doğrul A, Gül H, Yıldız O, Bilgin F, Güzeldemir ME. Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 2004; 368:82-86.
36. Shabani M, Zangiabadi N, Asadi-Shekaari M. Evidence for positive effects of date extract that attenuates thermal hyperalgesia in a diabetic rat model of neuropathic pain. Neurosci Med 2013; 4:16-22.
37. Manschot SM, Gispen WH, Kappelle LJ, Biessels GJ. Nerve conduction velocity and evoked potential latencies in streptozotocin‐diabetic rats: effects of treatment with an angiotensin converting enzyme inhibitor. Diabetes Metab Res Rev 2003; 19:469-477.
38. Fox A, Eastwood C, Gentry C, Manning D, Urban L. Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain 1999; 81:307-316.
39. Ohsawa M, Mizoguchi H, Narita M, Narita M, Kamei J, Nagase H, et al. Effects of a μ-opioid receptor agonist on G-protein activation in streptozotocin-induced diabetic mice. Eur J Pharmacol 2000; 401:55-58.
40. Mao J, Price D, Lu J, Keniston L, Mayer D. Two distinctive antinociceptive systems in rats with pathological pain. Neurosci Lett 2000; 280:13-16.
41. Fuentes J, Ruiz-Gayo M, Manzanares J, Vela G, Reche I, Corchero J. Cannabinoids as potential new analgesics. Life Sci 1999; 65:675-685.
42. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63:569-611.
43. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Therapeut 2002; 95:127-135.
44. Herzberg U, Eliav E, Bennett G, Kopin IJ. The analgesic effects of R (+)-WIN 55,212–2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 1997; 221:157-160.
45. Calcutt NA. Experimental models of painful diabetic neuropathy. J Neurol Sci 2004; 220:137-139.
46. Kakinoki B, Sekimoto S, Yuki S, Ohgami T, Sejima M, Yamagami K, et al. Orally active neurotrophin-enhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals. Diabetes 2006; 55:616-621.
47. Courteix C, Eschalier A, Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993; 53:81-88.
48. Ulugol A, Karadag HC, Tamer M, Firat Z, Aslantas A, Dokmeci I. Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats. Neurosci Lett 2002; 328:129-132.
49. Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol 1980; 20:441-462.
50. Hohmann AG, Briley EM, Herkenham M. Pre-and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999; 822:17-25.
51. Iversen L, Chapman V. Cannabinoids: a real prospect for pain relief. Curr Opin Pharmacol 2002; 2:50–55.
52. Bridges D, Rice A, Egertova M, Elphick M, Winter J, Michael G. Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience 2003; 119:803-812.
53. Xiao HS, Huang QH, Zhang FX, Bao L, Lu YJ, Guo C,et al. Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain. Proc Natl Acad Sci 2002; 99:8360-8365.
54. Hudson LJ, Bevan S, Wotherspoon G, Gentry C, Fox A, Winter J. VR1 protein expression increases in undamaged DRG neurons after partial nerve injury. Eur J Neurosci 2001; 13:2105-2114.
55. Hohmann AG, Martin WJ, Tsou K, Walker JM. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci 1995; 56:2111-2118.
Iranian Journal of Basic Medical Sciences
Volume 19, Issue 4
April 2016
Pages 394-401

Files

Share

How to cite

Statistics